Free tool
Drug Trial Radar: Neurology
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
104
Recruiting, industry sponsors, Neurology, Phase 3
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting104
- Completed1,034
104 trials
Showing 1 to 25, recently updated first.
- A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic MigrainePivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07729462 · 400 participants (planned) · Start Aug 26, 2026 · Primary completion Oct 21, 2028
Drug: Rimegepant; Placebo · For: Preventive Treatment of Migraine
Sites: Scottsdale, Arizona; Canoga Park, California; Fresno, California · 38 sites in all
- Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric SubjectsPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT05156398 · 640 participants (planned) · Start Feb 28, 2022 · Primary completion Mar 27, 2029
Drug: Rimegepant; Placebo · For: Migraine
Sites: Fort Smith, Arkansas; Hawthorne, California; La Mesa, California · 97 sites in all
- A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's DiseasePivotal-lookingRecruiting
Biohaven Therapeutics Ltd.Industry
NCT06976268 · 550 participants (planned) · Start May 28, 2025 · Primary completion Aug 2027
Drug: BHV-8000 10mg; BHV-8000 20 mg and 1 more · For: Parkinson Disease
Sites: Birmingham, Alabama; Sun City, Arizona; Irvine, California · 26 sites in all
- Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-2Pivotal-lookingRecruiting
Rapport Therapeutics Inc.Industry
NCT07594119 · 312 participants (planned) · Start Sep 1, 2026 · Primary completion Jul 2029
Drug: RAP-219; RAP-219 · For: Focal Seizure; Epilepsy; Focal Epilepsy
Sites: Huntsville, Alabama; Bentonville, Arkansas; Colorado Springs, Colorado · 17 sites in all
- Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of TJ0113 Capsules in Patients With Early-Onset Parkinson's DiseasePivotal-lookingRecruiting
Hangzhou PhecdaMed Co., Ltd.Industry
NCT07741045 · 300 participants (planned) · Start Nov 5, 2026 · Primary completion Jan 15, 2028
Drug: TJ0113 200mg; TJ0113 400mg and 1 more · For: Parkinson's Disease (PD); Parkinson Disease 6, Early-Onset
Sites: Beijing, China; Chongqing, China; Guangzhou, China · 21 sites in all
- A Study of Orelabrutinib in Patients With Secondary Progressive Multiple SclerosisPivotal-lookingRecruiting
Zenas BioPharma (USA), LLCIndustry
NCT07299019 · 990 participants (planned) · Start Mar 23, 2026 · Primary completion Jun 2030
Drug: Orelabrutinib; Placebo · For: Secondary Progressive Multiple Sclerosis
Sites: Phoenix, Arizona; Scottsdale, Arizona; Fullerton, California · 98 sites in all
- Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)Pivotal-lookingRecruiting
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyIndustry
NCT06463587 · 264 participants (planned) · Start Jun 25, 2024 · Primary completion Aug 23, 2028
Drug: Cladribine Low Dose; Cladribine High Dose · For: Generalized Myasthenia Gravis
Sites: Phoenix, Arizona; Longmont, Colorado; Farmington, Connecticut · 159 sites in all
- Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALSPivotal-lookingRecruiting
PrileniaIndustry
NCT07322003 · 500 participants (planned) · Start Feb 1, 2026 · Primary completion Mar 2028
Drug: Pridopidine; Placebo · For: Amyotrophic Lateral Sclerosis
Sites: Phoenix, Arizona; San Francisco, California; Aurora, Colorado · 56 sites in all
- A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)Pivotal-lookingRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06976203 · 586 participants (planned) · Start Jul 21, 2025 · Primary completion Sep 11, 2028
Drug: KarXT; KarX-EC · For: Alzheimer's Disease
Sites: Fullerton, California; Irvine, California; Los Angeles, California · 129 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06952504 · 1,123 participants (planned) · Start May 22, 2025 · Primary completion May 24, 2032
Drug: Pembrolizumab; Carboplatin and 4 more · For: Endometrial Cancer
Sites: Mobile, Alabama; Anchorage, Alaska; Irvine, California · 272 sites in all
- A Study to Evaluate the Safety and Efficacy of CBD-OS in Participants With DEEPivotal-lookingRecruiting
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
NCT07723976 · 120 participants (planned) · Start Oct 30, 2026 · Primary completion Sep 4, 2029
Drug: CBD-OS; Placebo · For: Developmental and Epileptic Encephalopathy (DEE)
Sites: Birmingham, Alabama; Phoenix, Arizona; Orange, California · 43 sites in all
- A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's DiseasePivotal-lookingRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06976216 · 586 participants (planned) · Start Jul 14, 2025 · Primary completion Sep 11, 2028
Drug: KarXT; KarX-EC · For: Alzheimer's Disease
Sites: Long Beach, California; Redlands, California; Basalt, Colorado · 119 sites in all
- A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07216703 · 1,023 participants (planned) · Start Jan 19, 2026 · Primary completion Oct 29, 2031
Drug: Pembrolizumab; Sacituzumab Tirumotecan and 5 more · For: Cervical Cancer
Sites: Birmingham, Alabama; Anchorage, Alaska; Irvine, California · 189 sites in all
- A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06623422 · 680 participants (planned) · Start Oct 21, 2024 · Primary completion May 16, 2033
Drug: Pembrolizumab; Cisplatin and 5 more · For: Carcinoma, Non-Small-Cell Lung
Sites: Gilbert, Arizona; Tucson, Arizona; Fullerton, California · 247 sites in all
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06966700 · 2,400 participants (planned) · Start Jun 30, 2025 · Primary completion Mar 23, 2033
Drug: Sacituzumab tirumotecan; Pembrolizumab and 8 more · For: Breast Neoplasms; Triple Negative Breast Neoplasms; HR Low-Positive/HER2-Negative Breast Neoplasms
Sites: Gilbert, Arizona; Phoenix, Arizona; Tucson, Arizona · 338 sites in all
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06841354 · 1,000 participants (planned) · Start Mar 16, 2025 · Primary completion May 18, 2030
Drug: Sacituzumab tirumotecan; Pembrolizumab and 5 more · For: Triple Negative Breast Neoplasms
Sites: Mobile, Alabama; Chandler, Arizona; Duarte, California · 285 sites in all
- Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1Pivotal-lookingRecruiting
Rapport Therapeutics Inc.Industry
NCT07563881 · 333 participants (planned) · Start Jun 5, 2026 · Primary completion Jul 2029
Drug: RAP-219; RAP-219 · For: Focal Seizure; Epilepsy; Focal Epilepsy
Sites: Birmingham, Alabama; Palmdale, California; San Francisco, California · 24 sites in all
- DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial CancerPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT06989112 · 600 participants (planned) · Start Mar 27, 2025 · Primary completion Jan 19, 2029
Drug: Trastuzumab deruxtecan; Rilvegostomig and 4 more · For: Endometrial Cancer
Sites: Tucson, Arizona; Little Rock, Arkansas; Duarte, California · 256 sites in all
- Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia GravisPivotal-lookingRecruiting
Immunovant Sciences GmbHIndustry
NCT07039916 · 231 participants (planned) · Start May 27, 2025 · Primary completion Dec 2027
Drug: IMVT-1402; IMVT-1402 and 2 more · For: Generalized Myasthenia Gravis
Sites: Huntsville, Alabama; Mobile, Alabama; Phoenix, Arizona · 93 sites in all
- A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of MigrainePivotal-lookingRecruiting
TriGemX Bio, Inc.Industry
NCT07816367 · 1,500 participants (planned) · Start Oct 2, 2026 · Primary completion Oct 2027
Drug: Elismetrep; Placebo · For: Migraine
Sites: Glendale, Arizona; Phoenix, Arizona; Little Rock, Arkansas · 72 sites in all
- Efficacy and Safety of BR005-036C Tablets for the Acute Treatment of Migraine in AdultsPivotal-lookingRecruiting
Brise Pharmaceuticals Co., Ltd.Industry
NCT07792681 · 2,079 participants (planned) · Start Sep 30, 2026 · Primary completion Jun 30, 2028
Drug: BR005-036C; BR005-036C and 1 more · For: Migraine, With or Without Aura
Sites: Shanxi, China; Inner Mongolia, China; Beijing, China · 81 sites in all
- A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic EpilepsyPivotal-lookingRecruiting
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
NCT07723963 · 260 participants (planned) · Start Sep 18, 2026 · Primary completion Aug 1, 2028
Drug: JZP926 capsule; Placebo · For: Juvenile Myoclonic Epilepsy
Sites: Phoenix, Arizona; Los Angeles, California; Sacramento, California · 23 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06345729 · 348 participants (planned) · Start May 24, 2024 · Primary completion Jan 24, 2028
Drug: Calderasib; Pembrolizumab · For: Non-small Cell Lung Cancer
Sites: Bakersfield, California; Beverly Hills, California; Stamford, Connecticut · 248 sites in all
- A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)Pivotal-lookingRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06937229 · 650 participants (planned) · Start Dec 2, 2025 · Primary completion Jun 22, 2029
Drug: KarXT; KarX-EC · For: Alzheimer Disease; Agitation
Sites: Chandler, Arizona; Scottsdale, Arizona; Anaheim, California · 255 sites in all
- A Study of Orelabrutinib in Patients With Primary Progressive Multiple SclerosisPivotal-lookingRecruiting
Zenas BioPharma (USA), LLCIndustry
NCT07067463 · 705 participants (planned) · Start Mar 23, 2026 · Primary completion Jun 2030
Drug: Orelabrutinib; Placebo · For: Multiple Sclerosis (MS) Primary Progressive
Sites: Pheonix, Arizona; Scottsdale, Arizona; West Hollywood, California · 86 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.